National and Kapodistrian University of Athens
Σύνθεση, κινητική και κρυσταλλογραφική µελέτη δυνάµει αναστολέων της φωσφορυλάσης του γλυκογόνου
Abstract
dc:descriptionDiabetes mellitus is a chronic metabolic non-communicable disease that results from abnormal glucose metabolism. The subsequent increase of glycaemia induces a number of health complications. Diabetes mellitus is one of the earliest diseases known to humans, yet, in our days it is considered as a pandemia, with severe global, economic and social consequences. Although there is no complete therapy, the disease can be controlled initially through changes in the patient’s lifestyle and afterwards through administration of antidiabetic drugs such as biguanides (metformin), sulfonylureas and insulin at increasing dosages, with the aim of controlling blood glucose levels. Unfortunately, accomplishment of the therapeutic targets usually fails and current drugs are responsible for serious side-effects. Therefore, there is a need for discovery of new drugs with improved pharmacological properties against diabetes mellitus. Since liver is the organ mainly responsible for glucose metabolism, various hepatic proteins have been used as macromolecular targets for the development of new therapies, in particular glucagon receptor (GR), glucose-6-phosphate phosphatase (G6PASE), fructose-1,6-diphosphate phosphatase (F16BPASE), hexokinase IV (GK) and glycogen phosphorylase (GP), the last being the topic of the current thesis. GP is a key enzyme for glycogen breakdown in liver and its active form (GPa) catalyzes the first step of phosphorolysis of glycogen to glucose. According to previous studies conducted by us and others, GP is a validated molecular target for the design and development of new potential inhibitors of glycogenolysis, with the ultimate goal to regulate blood glucose levels. Various compounds have been designed through the structure-basedintelligent-drug-design approach, as inhibitors of GP. In our laboratory, 4-substituted-βD-glucopyranosyl-pyrimidines have been developed which bind strongly at the catalytic site of the enzyme. The goal of this thesis was (a) the development of an optimized and versatile synthetic scheme that allows easy access to N4-aryl- and alkyl- substituted β-D-glucopyranosylcytosines; (b) the application of the new synthetic scheme in the development of a synthetically broad set of arylamines and alkylamines which include new characteristic groups at position 4- of the above lead compounds; (c) the kinetic study of the inhibition exerted by the above compounds at the in vitro activity of GP; (d) the crystallographic study of enzyme:inhibitor complexes with the aim of deciphering the interactions between them, mainly inside the β-channel of the catalytic site, and which can explain the observed inhibition and (e) the extraction of a map of positive interactions. From the perspective of chemical synthesis, various methods of activation of β-Dglucopyranosyl-uracil at position 4- were studied and found that the combination of Ν1(2,3,4,6-tetra-Ο-acetyl)-β-D-glucopyranosyl--(1,2,4-triazol-yl)pyrimidin-2-one with microwave irradiation led to a facile, versatile and high yielding total synthetic route. In this manner, 17 new potential inhibitors of GP were synthesized (p. 7, compounds 60b and 63b were already synthesized and utilized in this thesis as leads), and subsequently studied through enzyme kinetics towards their inhibitor potency. By determining their IC50 values as well as the Ki values for the most potent of them, a number of low nM inhibitors have been discovered and, most importantly, the second most potent up-to-date inhibitor for the catalytic site of GP, Ν1-β-D-glucopyranosyl-Ν4[4-acridin-9(10Η)-oxo]cytosine (90b, p. 7) with Ki = 71 nM. The binding mode of the new inhibitors as complexes with GP was studied with X-ray crystallography. Detailed mapping of the inhibitor interactions with the catalytic site of the enzyme and the knowledge derived from it, helped explain the kinetic results and correlate them with the inhibitor structure. The interaction map was exploited in the design and synthesis of compounds with improved characteristics. Finally, the best inhibitors were tested in a series of preliminary biological experiments for the evaluation of their ability to regulate glycaemia in vivo.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2015
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Mamais, Michail
- Μαμάης, Μιχαήλ
Subjects
dc:subject × 18- Ανακάλυψη φαρμάκων
- Διαβήτης
- Φωσφορυλάση του γλυκογόνου
- Αναστολείς
- Νουκλεοζίτες
- Πρωτεϊνική κρυσταλλογραφία ακτίνων Χ
- Κατευθυνόμενος από τη δομή σχεδιασμός φαρμάκων
- Drug discovery
- Diabetes
- Glycogen phosphorylase
- Inhibitors
- Nucleosides
- X-ray protein crystallography
- Structure-based drug design
- Φυσικές Επιστήμες
- Χημεία
- Natural Sciences
- Chemical Sciences
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/44645